Human M-CSF R/CD115 Alexa Fluor® 594-conjugated Antibody Summary
rhGM-CSF R beta.
Ile20-Glu512 (Pro54Ala)
Accession # P07333.2
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
Background: M-CSF R/CD115
M-CSF receptor, the product of the c-fms proto-oncogene, is a member of the type III subfamily of receptor tyrosine kinases that also includes receptors for SCF and PDGF. These receptors each contain five immunoglobulin-like domains in their extracellular domain (ECD) and a split kinase domain in their intracellular region (1‑4). M-CSF receptor is expressed primarily on cells of the monocyte/macrophage lineage, dendritic cells, stem cells and in the developing placenta (1). Human M-CSF receptor cDNA encodes a 972 amino acid (aa) type I membrane protein with a 19 aa signal peptide, a 493 aa extracellular region containing the ligand-binding domain, a 25 aa transmembrane domain, and a 435 aa cytoplasmic domain. The human M-CSF R ECD shares 60%, 64%, 72%, 75%, 75%, and 76% aa identity with mouse, rat, bovine, canine, feline, and equine M-CSF R, respectively. Activators of protein kinase C induce TACE/ADAM17 cleavage of the M-CSF receptor, releasing the functional ligand-binding extracellular domain (5). M-CSF binding induces receptor homodimerization, resulting in transphosphorylation of specific cytoplasmic tyrosine residues and signal transduction (6). The intracellular domain of activated M-CSF R binds more than 150 proteins that affect cell proliferation, survival, differentiation and cytoskeletal reorganization. Among these, PI3Kinase, P42/44 ERK, and c-Cbl are key transducers of M-CSF R signals (3, 4). M-CSF R engagement is continuously required for macrophage survival and regulates lineage decisions and maturation of monocytes, macrophages, osteoclasts and DC (3, 4). M-CSF R and integrin alpha v beta 3 share signaling pathways during osteoclastogenesis and deletion of either causes osteopetrosis (7, 8). In the brain, microglia expressing increased M-CSF R are concentrated with Alzheimers a beta peptide, but their role in pathogenesis is unclear (9, 10).
- deParseval, N. et al. (1993) Nucleic Acids Res. 21:750.
- Rothwell, V.M. and L.R. Rohrschneider (1987) Oncogene Res. 1:311.
- Chitu, V. and E.R. Stanley (2006) Curr. Opin. Immunol. 18:39.
- Ross, F.P. and S.L. Teitelbaum (2005) Immunol. Rev. 208:88.
- Rovida, E. et al. (2001) J. Immunol. 166:1583.
- Yeung, Y. et al. (1998) J. Biol. Chem. 273:17128.
- Dai, X. et al. (2002) Blood 99:111.
- Faccio, R. et al. (2003) J. Clin. Invest. 111:749.
- Li, M. et al. (2004) J. Neurochem. 91:623.
- Mitrasinovic, O.M. et al. (2005) J. Neurosci. 25:4442.
Product Datasheets
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human M-CSF R/CD115 Alexa Fluor® 594-conjugated Antibody
Average Rating: 5 (Based on 2 Reviews)
Have you used Human M-CSF R/CD115 Alexa Fluor® 594-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Blood of 1 healthy human donor was stained for identification of monocytes using the AF594-conjugated anti-MCSF/CD115 antibody. Monocytes were first identified among total leukocytes (CD45+) and then confirmed as CD115+ using this antibody. spillover into other channels was corrected for after compensation.
Human peripheral blood was stained and analyzed by flow cytometry. Monocytes were identified among CD45+ leukocytes and analyzed for CD115 expression (M-CSF receptor). This antibody was detected in the PE-TR channel (610/20) and signal was maintained upon fixation by paraformaldehyde
